Sobril

SECTION 2: Hazards identification

Appearance: Round, white tablet

Hazard statements

Suspected of causing cancer. Suspected of damaging fertility or the unborn child. May cause damage to gastrointestinal system and central nervous system through prolonged or repeated exposure. Known Clinical Effects: Adverse effects most commonly reported in clinical use include drowsiness and lethargy Other less common effects include dizziness vertigo headache fainting (syncope) Drugs of this class may cause symptoms of dependence/withdrawal This material has been shown to be secreted in low concentrations in human breast milk. This compound can cross the placenta in pregnant women. EU Indication of danger: Carcinogenic: Category 3 Toxic to Reproduction; Category 3 EU Hazard Symbols: EU Risk Phrases: R40 - Limited evidence of a carcinogenic effect R62 - Possible risk of impaired fertility. R63 - Possible risk of harm to the unborn child. Australian Hazard Classification

Hazardous Ingredients

Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.